For Immediate Release

Core Technology Alliance Appoints Executive Director
John C. Greenfield brings 25 years of drug discovery, clinical and
business development experience to the job
 
Grand Rapids, Michigan (March 8, 2007) – This week, George F. Vande Woude, Ph.D., president and CEO of the Core Technology Alliance (CTA), announced the appointment of John C. Greenfield, Ph.D., as executive director of the CTA.  Dr. Greenfield will direct the CTA Corporation’s marketing and development strategy; represent the alliance among CTA core directors, customers, industry partners and government collaborators; and cultivate the CTA scientific team and work force.

“Dr. Greenfield brings a tremendous depth of experience to this position,” stated Dr. Vande Woude, who is also director of the Van Andel Research Institute.  “He has over 25 years of scientific and business experience in the pharmaceutical industry including drug discovery, preclinical and clinical development, project management, business development and licensing, and medical and drug information.”

Dr. Greenfield earned a Bachelor of Science in chemistry from Ohio University, Athens, OH, and a Doctor of Philosophy in organic and biochemistry from the University of Illinois, Urbana-Champaign.  Later, he was a North Atlantic Treaty Organization (N.A.T.O.) post-doctoral fellow in bio-organic chemistry at the Swiss Federal Institute of Technology in Zürich, Switzerland.
 
Dr.  Greenfield joined The Upjohn Company in 1976 as a research scientist and has over 25 years of scientific and business experience at Upjohn and legacy pharmaceutical companies. Most recently, he co-founded and served as vice president of business development at BioMedPharmIS, Ltd., a successful legacy Pharmacia start-up company in Kalamazoo.
 
 “I am very pleased to join the CTA and look forward to contributing to its continued growth and success,” stated Dr. Greenfield.  “This is an exciting time for the Michigan life sciences sector, particularly for the CTA as we welcome our seventh member and 10th core.   The cutting-edge technologies provided by the CTA will enable the growth of high technology businesses throughout the State of Michigan.”
 
Formed in 2000 as an initiative of the former Michigan Life Sciences Corridor, the CTA was incorporated in 2004 and makes sophisticated core technologies available on a fee-for-service basis to biotech and pharmaceutical firms, entrepreneurs and researchers both inside and outside Michigan. By creating greater access to these technologies, the CTA serves as a catalyst for biotech R&D and development of the life science industry throughout the state.  The non-profit organization remains a key initiative of the Technology Tri-Corridor, providing leadership, oversight and commercialization to Michigan’s core facility infrastructure and working to further develop cutting-edge core technologies.
 
CTA members include Grand Valley State University, Kalamazoo Valley Community College, Michigan State University, the University of Michigan, the Van Andel Research Institute, Wayne State University and Western Michigan University. The alliance’s existing core facilities are dedicated to genomics, proteomics, structural biology, animal models, bioinformatics, high throughput screening, antibody technology, pathology services and clinical stage pharmaceutical contract manufacturing services.